Investigations

A Medical Cost-Sharing Plan Left Pastor With Most Of The Cost

Jeff and Kareen King joined a medical cost-sharing plan advertised as a “refreshing non-insurance approach” to paying for health care. It had a big proviso: Preexisting conditions like Jeff’s heart condition were not fully covered for the first two years. He needed heart surgery after just 16 months.

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.

$38,398 for a Single Shot of a Very Old Cancer Drug

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?